All grade 3 and 4 patients already had leukemia or therapy-related cytopenia before the immunotherapy: grade 2 (A002) or 3 (A006 and A008) lymphopenia, grade 2 (A006) or 3 (A005) neutropenia, and grade 2 (A002) leukopenia before the aAVC-WT1 therapy. This evidence concerns the gene WT1 and neutropenia.